Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED® lamp, Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo. In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
We have brought together a committed and experienced leadership team with an established track record in commercialization of specialty dermatology products and late stage clinical development in an entrepreneurial environment.
Our Board is comprised of experienced individuals who help guide Biofrontera Inc. as we grow to become a leading U.S.-based biopharmaceutical company commercializing a portfolio of FDA-approved products for the treatment of dermatological conditions.
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED® lamp, Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo. In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Our Board of Directors sets high standards for our employees, officers and directors. Sound corporate governance is an integral part of our efficient and effective operation. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of our business. Our Board of Directors follows the procedures and standards that are set forth in our Code of Business Conduct and Ethics and the charters of the standing committees of the Board of Directors. The Code of Conduct and the charters are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Board Diversity Matrix for BFRI – Biofrontera Inc.
As of 9/1/2022
|
Total Number of Directors |
5 |
| Part I: Gender Identity | Female | Male | Non-Binary |
Did Not Disclose Gender |
|---|---|---|---|---|
|
Directors |
2 |
3 |
|
|
| Part II: Demographic Background | ||||
|---|---|---|---|---|
|
African American or Black |
|
|
|
|
|
Alaskan Native or American Indian |
|
|
|
|
|
Asian |
|
|
|
|
|
Hispanic or Latinx |
|
|
|
|
|
Native Hawaiian or Pacific Islander |
|
|
|
|
|
White |
1 |
3 |
|
|
|
Two or More Races or Ethnicities |
|
|
|
|
|
LGBTQ+ |
|
|
|
|
|
Did Not Disclose Demographic Background |
|
1 |
|
|
120 Presidential Way, Suite 330
Woburn, MA 01801
1-781-245-1325
info-us@biofrontera.com
Investor Relations
ir@bfinc.com
120 Presidential Way, Suite 330
Woburn, MA 01801
1-781-245-1325
info-us@biofrontera.com
INVESTOR RELATIONS CONTACT
Pamela Keck
+49-214-87632-92
us-ir@biofrontera.com
© Copyright 2021, Biofrontera Corp. All rights reserved.
